Novartis CAR-T therapy leads to durable response in lymphoma study Ruby Khatun Khatun11 Dec 2017 5:15 AMPatients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy...